shortage of glp-1 receptor agonists The impact agonist shortages on glycaemic Control: Findings from an Australian specialist diabetes clinic Government declares 'national shortage' of
Description
doi: 10.1093/eurheartj/ehz486
For example, GI symptoms are more commonly reported when patients are evaluated at a tertiary referral centre compared with a community setting, but allowing for this, estimates suggest up to 70% of people with diabetes are affected
Novo Nordisk also launched an oral tablet form of Wegovy in 2025, making it the first oral GLP-1 approved for weight loss
GLP-1 receptor agonists such as exenatide, liraglutide, semaglutide, and dulaglutide are already approved for treating Type 2 diabetes mellitus and obesity, which interests researchers in further research
PMCID: PMC9510507
